Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3

<p><b>Purpose:</b> To evaluate short- and long-term efficacy and safety of ixekizumab in patients according to psoriasis severity.</p> <p><b>Materials and methods:</b> Data were integrated from clinical trials (UNCOVER-2, UNCOVER-3). Patients received placebo, 80-mg ixekizumab every 2 weeks (IXEQ2W), every 4 weeks (IXEQ4W), or 50 mg etanercept (ETN) biweekly for 12 weeks, then open-label IXEQ4W (UNCOVER-3). Psoriasis severity was categorized by baseline Psoriasis Area and Severity Index (PASI <20 and ≥20). Efficacy was evaluated by percentage reaching PASI 75, 90, 100, and absolute PASI ≤5, ≤2, and ≤1.</p> <p><b>Results:</b> Significantly more patients with PASI ≥20 (vs. PASI <20) were male and had higher body weight. After 12 weeks, both severity groups had significantly more IXEQ2W- than ETN-treated patients reach PASI 75, 90, 100, and absolute PASI ≤5, ≤2, ≤1. Fewer PASI ≥20 vs. PASI <20 patients across treatments reached PASI ≤5, ≤2, and ≤1 at week 12. Efficacy was maintained during 156 weeks of ixekizumab treatment with no differences between groups. The IXEQ2W safety profile was similar between groups except for injection-site reactions (significantly higher in PASI <20).</p> <p><b>Conclusions:</b> Ixekizumab demonstrated a high level of efficacy and had a consistent safety profile in patients with different baseline psoriasis severity levels.</p

Odds of escalation of treatment and odds of using topical anti-inflammatory medication by change in bother score compared to the previous day.

<p>Odds of escalation of treatment and odds of using topical anti-inflammatory medication by change in bother score compared to the previous day.</p

Baseline characteristics of included participants.

<p>¹ There was 1 missing value for SASSAD in Study A, and I missing value for POEM in both Study A and Study B.</p><p>Abbreviations: Standard Deviation (SD), Patient Oriented Eczema Measure (POEM), Six Area, Six Sign Atopic Dermatitis (SASSAD), Not applicable (N/A)</p><p>Baseline characteristics of included participants.</p

Proportion of days in flare by mean POEM scores for AE severity.

<p>Proportion of days in flare by mean POEM scores for AE severity.</p

Study selection flow chart.

<p>Study selection flow chart.</p

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

Article full text The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days. The above features represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).  © The authors, CC-BY-NC 2024</p